D. Patricia

A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies

D. Ouellet, L. D. De Zwart, J. Snoeys, 2018, Leukemia & lymphoma.

A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies

G. Nicholas, A. Gupta, L. Chow, 2013, Cancer Chemotherapy and Pharmacology.

Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer

C. Drake, E. Antonarakis, D. McNeel, 2019, Prostate Cancer and Prostatic Diseases.

Chapter 2 Candidemia

R. Neves, D. Patricia, R. Lima-Neto, 2016 .

Metabolism, Excretion, and Pharmacokinetics of Oral Brivanib in Patients with Advanced or Metastatic Solid Tumors

T. Mekhail, R. Ganapathi, J. Gan, 2010, Drug Metabolism and Disposition.

Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer.

M. Morris, J. Wong, C. Divgi, 2022, Journal of Clinical Oncology.

A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies

D. Ouellet, J. Snoeys, J. Jiao, 2018, Leukemia & lymphoma.

Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer

C. Drake, E. Antonarakis, D. McNeel, 2021, Prostate Cancer and Prostatic Diseases.